N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy
about
A sting in the tail: the N-terminal domain of the androgen receptor as a drug targetDrug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategiesEmerging data on androgen receptor splice variants in prostate cancerRegistered report: androgen receptor splice variants determine taxane sensitivity in prostate cancerDevelopment and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanesAndrogen receptor splice variants circumvent AR blockade by microtubule-targeting agentsAndrogen pathway resistance in prostate cancer and therapeutic implicationsMultinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate CancerCotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate CancerMoving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.Chemotherapy in Prostate Cancer.Mechanisms of Therapeutic Resistance in Prostate Cancer.Rh2E2, a novel metabolic suppressor, specifically inhibits energy-based metabolism of tumor cells.Androgen receptor variation affects prostate cancer progression and drug resistance.Anoikis and EMT: Lethal "Liaisons" during Cancer Progression.Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.Profiling Prostate Cancer Therapeutic Resistance.Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants
P2860
Q26747094-9ADF0D89-0C02-4B6B-A8E7-74457A2EAC88Q26796704-0F408B75-B5DE-41BC-AECC-1382DC0317B0Q28077830-CB44BE00-222C-4F41-8E6F-585C4634780DQ28607383-D1113FE9-6C5A-4FD3-BA20-05D154AB0151Q30276797-813C9396-9CFA-42B0-A6EB-FC06C8730F45Q34495028-A1AEF099-7A47-476C-BB1F-E30EDB2EE4F3Q35856517-90D29CB8-EDC1-48FF-9BD6-459B9A00FFF7Q36414184-BA8E0D0D-1148-43C3-87C5-C8EE72A2BA72Q36416370-04138BFB-1CD0-4206-876C-502606F6DB2FQ36586089-930FD5F6-59F3-4D2A-81EB-9477AFBD9B7CQ36963697-06BE62E2-4D8C-4275-8523-FB3CF3A7A5A4Q37737611-565C5D63-8D29-4D5D-9831-7A8192A4C5D5Q38555599-66A78781-4DCE-45D3-A461-7E554E10490EQ38754316-A658A2DE-6973-473A-9F4D-0B57B3F72C8CQ38800502-B182AC2A-431B-40D1-B53C-9A1E0971491EQ38977288-045E44CA-CF98-4994-BB54-FADAD98E7706Q39028687-43D8127E-5C90-4AB4-9FD8-1093D34CABF1Q40355149-7BE083E3-DA2B-4744-A418-459CED01A2BFQ52644478-DED2D900-CFC5-4FF0-AD79-1B81D2CAFBEDQ53735518-D77EA811-A0A8-4970-8DEA-6B7B1DCF8819Q58697074-464383AA-3F7D-488F-8D72-63EEF87D1A81
P2860
N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
N-terminal targeting of androg ...... cancer to taxane chemotherapy
@ast
N-terminal targeting of androg ...... cancer to taxane chemotherapy
@en
type
label
N-terminal targeting of androg ...... cancer to taxane chemotherapy
@ast
N-terminal targeting of androg ...... cancer to taxane chemotherapy
@en
prefLabel
N-terminal targeting of androg ...... cancer to taxane chemotherapy
@ast
N-terminal targeting of androg ...... cancer to taxane chemotherapy
@en
P2093
P2860
P1433
P1476
N-terminal targeting of androg ...... cancer to taxane chemotherapy
@en
P2093
Carmen A Banuelos
Natasha Kyprianou
Sarah K Martin
P2860
P356
10.1016/J.MOLONC.2014.10.014
P50
P577
2014-11-15T00:00:00Z